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ABSTRACT: Natural products profoundly impact many research areas, including
medicine, organic chemistry, and cell biology. However, discovery of new natural
products suﬀers from a lack of high throughput analytical techniques capable of
identifying structural novelty in the face of a high degree of chemical redundancy.
Methods to select bacterial strains for drug discovery have historically been based on
phenotypic qualities or genetic diﬀerences and have not been based on laboratory
production of secondary metabolites. Therefore, untargeted LC/MS-based secondary
metabolomics was evaluated to rapidly and eﬃciently analyze marine-derived bacterial
natural products using LC/MS-principal component analysis (PCA). A major goal of this
work was to demonstrate that LC/MS-PCA was eﬀective for strain prioritization in a
drug discovery program. As proof of concept, we evaluated LC/MS-PCA for strain selection to support drug discovery, for the
discovery of unique natural products, and for rapid assessment of regulation of natural product production.
N
atural products are genetically encoded small molecules
that have had a profound impact on many research areas
including medicine, organic chemistry, and cell biology.
1
Between 1981 and 2010, natural products or their derivatives
accounted for 74% and 59% of antibacterial and anticancer new
chemical entities (NCEs), respectively;
2 natural products
remain an important source for drug discovery
3 and continue
to inspire synthetic organic chemistry with their superlative
architectural complexity.
4 Natural products have also made
important contributions to cell biology due to their outstanding
potency and speciﬁcity. For example, rapamycin helped
elucidate the many complexities of mTOR (mammalian target
of rapamycin) signaling.
5
While bacterially produced natural products continue to be
an important source for therapeutic discovery, ﬁnding novel
natural products has become more diﬃcult, and new methods
are greatly needed. Genomics-based methods, such as genome
mining
6 and metagenomics,
7,8 hold great promise for discovery
of novel natural products and new biosynthetic pathways but, at
present, are diﬃcult to integrate with contemporary targeted
high-throughput screening (HTS).
1,9,10 With respect to culture-
dependent methods, immense bacterial and chemical diversity
remains undiscovered.
11 Whole genome sequencing of bacteria
and fungi has demonstrated that only a small fraction of the
“parvome” has been discovered.
12,13 In particular, the marine
environment contains a wealth of undiscovered bacteria and
bacterial natural products.
14 We have focused on actinomycetes
from underexplored niches, marine invertebrates such as
sponges and ascidians, as a source of bacterial diversity and
chemical diversity for drug discovery.
With respect to drug discovery, analytical technology
development has greatly assisted with building fractionated
natural product libraries that are compatible with HTS.
15,16 The
success of HTS is inherently dependent on chemical diversity
and a lack of chemical redundancy.
3,17 Historically, natural
product extract sources were chosen either randomly or on the
basis of their ecology and/or taxonomy. For bacteria chemical
diversity was not determined prior to extraction, leading to
redundant strains and compounds in many natural product
extract libraries.
18 In order to overcome this historical weakness
that led to high rates of rediscovery, methods based on the
genetic potential of a microorganism to produce natural
products were used.
19,20 Importantly, cultivated strains may
appear identical, but produce diﬀerent secondary metabolites.
21
Alternatively, strains that appear diﬀerent by morphology and
16S sequencing could produce the same secondary metabolites.
Therefore, we hypothesized that a chemoinformatics method
based on secondary metabolite production in the lab would be
more valuable and would greatly increase the value of a
screening library for HTS. We embraced methods from
metabolomics since they were designed, in part, to analyze
large numbers of compounds without complete knowledge of
the structure.
Metabolomics is the global measurement of the small
molecule metabolites in a biological system and reﬂects the
phenotype of (and is therefore complementary to) its
underlying genomic, transcriptomic, and proteomic networks.
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such as LC/MS to globally measure small molecule
metabolites.
22−25 Combining principal component analysis
(PCA) with LC/MS is an attractive method to provide a
visual representation of variance between LC/MS proﬁles. We
hypothesized that bacterial strains producing the same
secondary metabolites would group together, whereas those
producing diﬀerent metabolites would be separated, thereby
providing a method to select bacteria having distinct
chemistries without having to identify each component of
their corresponding extracts. A major distinction between the
work presented here and other metabolomics studies is that we
focused on secondary metabolites rather than primary
metabolites.
The goal of this study was to evaluate LC/MS-PCA based
secondary metabolomics to more broadly investigate secondary
metabolites from marine invertebrate-associated bacteria to
assist with strain selection/dereplication to support drug
discovery eﬀorts, to distinguish taxonomically identical species,
to discover new natural products, and to study regulation of
secondary metabolite production. Compared with conventional
manual comparison among LC/MS traces, PCA signiﬁcantly
increased the eﬃciency of these studies (Figure 1).
■ EXPERIMENTAL SECTION
Ascidian Collection and Bacterial Cultivation. See
Supporting Information.
Sample Preparation for UHPLC/HRESI-TOF-MS. Proce-
dure for Fermentations. An aliquot (1.5 mL) of each
fermentation was transferred to a clean microcentrifuge tube
(1.7 mL) and centrifuged at 10000 rpm for 1 min. The
supernatant (1 mL) was transferred into a clean vial and placed
on a Gilson GX-271 liquid handling system. The supernatant
was subjected to automated SPE (Biotage: EVOLUTE ABN,
25 mg absorbent mass, 1 mL reservoir volume), washed using
H2O (1 mL) to remove media components/primary
metabolites, and eluted with MeOH (1 mL) directly into an
LC/MS-certiﬁed vial. While removal of primary metabolites by
SPE cannot be guaranteed, we have not observed primary
metabolites in our analyses to date. All compounds that have
been observed as aﬀecting the PCA have been secondary
metabolites. EVOLUTE ABN was selected because it was
optimized as a phase to concentrate drug-like compounds. Two
biological replicates were prepared for each bacterial strain.
Procedure for Agar-Based Solid Media. For Streptomyces
spp., we sampled directly oﬀ solid agar media. Two cores (8
mm diameter) of bacteria and agar were obtained from each
plate, placed directly into MeOH (2 mL), and extracted for 30
min. The extract was transferred into a clean vial and
evaporated using a SpeedVac concentrator; the residue was
dissolved in MeOH (100 μL), followed by addition of H2O( 1
mL). The solution was then placed on a Gilson GX-271 liquid
handling system and subjected to automated SPE as described
above.
UHPLC/HRMS Analysis. LC/MS data were acquired using a
Bruker MaXis ESI-Q-TOF mass spectrometer coupled with a
Waters Acquity UPLC system operated by Bruker Hystar
software. A Phenomenex 2.6 μm core−shell column was
selected because it provides comparable results to fully porous
sub-2-μm particles while generating much lower back pressure
at the same velocity. Therefore, the core−shell particles can be
used not only on a UHPLC system but also on a standard
HPLC system.
26−28 A gradient of MeOH and H2O (containing
0.1% formic acid) was employed with a ﬂow rate of 0.3 mL/
min on an RP C-18 column (Phenomenex Kinetex 2.6 μm, 2.1
mm × 100 mm). The gradient started from MeOH/H2O
(10%/90%), followed by a linear gradient to reach MeOH/
H2O (97%/3%) in 12 min, and held for 2 min at MeOH/H2O
(97%/3%). Full scan mass spectra (m/z 150−1550) were
measured in positive ESI mode. MS data were acquired under
(+)-ESI based on experience and a recent paper,
29 where 93%
of the tested 719 microbial natural product and mycotoxin
reference standards were detected using (+)-ESI positive mode.
The mass spectrometer was operated using the following
parameters: capillary, 4.5 kV; nebulizer pressure, 4.0 bar; dry
gas ﬂow, 6.0 L/min; dry gas temperature, 200 °C; scan rate, 2
H z .T u n em i x( A g i l e n t ,E S I - Ll o wc o n c e n t r a t i o n )w a s
introduced through a divert valve at the end of each
chromatographic run for automatic internal calibration. Data-
dependent MS/MS data were acquired using the following
additional parameters: number of precursors, 3; absolute
threshold, 2000; summation factor, 1.0×. Isolation width and
collision energy were applied on the basis of isolation mass
value and charge state against a table of isolation and
fragmentation lists (see Table S1 in Supporting Information).
Data Processing and PCA. Bruker Data Analysis 4.0 was
used for analysis of chromatograms. Molecular formulas were
predicted using Bruker SmartFormula algorithm, which uses
Figure 1. Flowchart for UHPLC/HRMS-based secondary metabolomics.
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30 Bucketing LC/MS data
and PCA was performed using Bruker ProﬁleAnalysis 2.0. The
detailed parameters for advanced bucketing and PCA can be
found in the Additional Experimental Section in the Supporting
Information. Freely available software packages, such as
XCMS
31 and MZMine,
32 can also be used for raw LCMS
data preprocessing to generate feature tables, which can be used
for PCA in software, such as SIMCA, MATLAB, and freely
available packages for R. We compared using XCMS in
combination with PCA analysis with R to conﬁrm that results
were similar. Compared with open-source software, Proﬁle
Analysis 2.0 provides dynamically linked scores plot, loadings
plot, and bucket statistics plot, which is convenient and eﬃcient
for data mining.
■ RESULTS AND DISCUSSION
Data Preprocessing and PCA. In Proﬁle Analysis 2.0, a
molecule feature ﬁnding algorithm was employed to extract
compound signals from background noise.
31 Advanced
bucketing applied an internal hierarchical clustering algorithm
to construct buckets with given sizes of retention time (RT)
and m/z around picked compounds followed by generation of a
bucket table including RT−m/z pairs (buckets) and intensities.
Importantly, the size of the retention time window must be
greater than the possible retention time variation between runs.
Compounds with diﬀerent charge states were deconvoluted
into a single RT−m/z pair (bucket).
33 Both line and proﬁle
spectra were subjected to PCA and showed identical results.
Thus, line spectra were selected, which signiﬁcantly reduced
calculation time. The bucket table was then subjected to PCA,
and the scores plots and the corresponding loadings plots were
analyzed using Proﬁle Analysis 2.0. Proﬁle Analysis greatly
assisted with analyzing PCA results. For example, the scores
plot presents a view of the variance in the data, and the further
groups separate, the more diﬀerent the secondary metabolites.
The loadings plot is geometrically related to the scores plot and
described the variance observed in the scores plot. Analysis of
any point in the loadings plot through selection with a mouse
provides a corresponding bucket statistics plot that shows the
intensity of the selected compound in all analyses that were
used for PCA. Additionally, a dynamically linked table
highlights the compound selected in the loadings plot. The
table contains the m/z−RT information, intensity, and the
accurate mass, which allows a quick analysis of putative
Figure 2. Strain selection by secondary metabolomics. (a) PCA scores plot (PC1 vs PC2) of 47 strains (Table S2 in Supporting Information).
Strains, designated by color and shape, were clustered on the basis of natural products detected by MS. G1−G7 represent group 1−group 7,
respectively, and are displayed in colored circles. (b) A heat map to display distinct metabolic proﬁles among the seven groups. (c) Phylogenetic tree
of the 47 strains. A comparison with the groups formed in the PCA scores plot is shown. Each group of strains was designated by a colored circle in
the PCA scores plot; strains within each circle were matched to the same color in the phylogenetic tree. WMMB-328 is a Streptomyces sp. and was
used as an outgroup.
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interactively analyze secondary metabolites greatly assisted
these studies and will be highlighted below.
Strain Selection by Secondary Metabolomics. Without
careful construction of a screening library, large screening
campaigns lead to identifying large numbers of known
compounds. Therefore, an eﬀective strain selection approach
is required to maximize chemical diversity and minimize
redundancy for discovery of therapeutic leads.
34,35 As a proof of
concept for strain selection, 47 strains (32 Verrucosispora spp., 5
Micromonospora spp., and 10 Nocardia spp. cultivated from
tropical ascidians, Trididemnum orbiculatum, Didemnum psam-
mathode, and Ecteinascidia turbinata) were analyzed by LC/MS
and PCA. (See Table S1 in Supporting Information for more
details on the strains.) The LC/MS data used for this research
has been made publicly accessible.
36 The Verrucosispora spp.
and Micromonospora spp. appeared identical on isolation plates
and provided a real world example of distinguishing strains
cultivated from marine invertebrates. In some cases these
bacteria were identical by morphology and 16S rDNA
sequences. After LC/MS and processing, a total of 26027
buckets and 74 principal components were generated and
explained 98% of the variation in the data set. Analysis of the
resulting scores plot (PC1 versus PC2) showed identiﬁable
groups. As stated in the Experimental Section, the loadings plot
was dynamically linked to the scores plot to facilitate
identiﬁcation of compounds that caused variance. After analysis
of the scores plot, 7 clustered groups were identiﬁed (Figure
2a). To address the question of whether selection by PCA
resulted in low chemical redundancy, we selected one
representative strain from each of the 7 clustered groups and
generated a heat map (Figure 2b). The heat map of metabolite
proﬁles showed little overlap and complementary chemical
space based on detected ions. Overall, this would greatly reduce
chemical redundancy in a screening library when strains were
selected on the basis of PCA.
We also compared and contrasted the use of secondary
metabolomics with phylogenetic trees generated from 16S
rDNA sequences (Figure 2c). In some cases, the grouping
observed in the PCA scores plot (Figure 2a) paralleled those
observed in the phylogenetic tree. For example, the G1 and G3
groups were dominated by Verrucosispora spp. On the other
hand, Verrucosispora spp. found in both G1 and G3 had
identical 16S sequences indicating that PCA provided ﬁner
resolution to distinguish strains compared to morphology and
16S comparisons. The results indicated that strains with nearly
identical 16S gene sequences do not necessarily produce the
same natural products and supported our approach for strain
selection based on natural product production. These results
are consistent with other published results where strains that
Figure 3. Discovery of natural products unique to the group 7. (a) PCA scores plot (PC1 vs PC2) of the 47 stains (Table S1 in Supporting
Information). (b) PCA loadings plot. The PCA loadings plot is geometrically related to the scores plot and can be used to identify the compounds
responsible for group patterns in the PCA scores plot. Compound 1 (RT 5.5 min m/z 600.7804, [M + 2H]2+) is one of the major contributors to
group 7. (c) The bucket statistic plot for 1 showing normalized intensities of 1 in the 47 strains. Compound 1 was only detected in group 7.
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sequences (>99% identity) can produce diﬀerent natural
products.
21 LC/MS-PCA proved useful for distinguishing
strains on the basis of laboratory production of secondary
metabolites. With respect to strain dereplication, LC/MS-PCA
could provide a selection criterion prior to 16S sequencing to
reduce the number of bacteria that need to be sequenced in a
drug discovery program.
A limiting factor to using PCA was that supporting
approaches were necessary to increase the scale. For example,
PCA would not be useful for analyzing 1000 strains at a time.
We have found that analysis of between 20 and 50 strains was
practical. For strain selection from a cultivated collection, we
use a combination of gross morphology and source organism to
classify groups to be analyzed by PCA. Additionally, analysis
can be performed on overlapping groups such that each
successive analysis contains some data from the previous
analysis. Combined with gross morphology, we have now
successfully analyzed over 500 strains with great success.
Discovery of Natural Products Unique to Speciﬁc
Strains. Previous work showed that natural products produced
by Myxococcus spp. could be rapidly mapped to producing
strains and novel natural products could be identiﬁed using
secondary metabolomics.
33,37 Therefore, we evaluated the
process for marine invertebrate associated bacteria. The
loadings plot was used to identify compounds that caused a
clustered group to separate. Again, Proﬁle Analysis allowed a
point and click in the loadings plot to observe the presence of
the compound in all analyzed strains. Additionally, an accurate
mass was obtained through the dynamically linked table. For
selected putative new natural products, isolation and structure
elucidation of those compounds was undertaken as described in
Supporting Information. In addition to conventional ap-
proaches, an LC-MS-SPE-NMR system
38 was used in
conjunction with 1H{13C,15N} 1.7 mm NMR cryogenic probe
to facilitate rapid structure elucidation.
As an example, compound 1 (RT 5.5 min-m/z 600.7804, [M
+ 2H]2+) (Figure 3b) was a signiﬁcant contributor to group 7
(Figure 3a) because 1 and group 7 were located in the same
quadrant in the loadings plot and the scores plot, respectively.
From the bucket statistics plot (Figure 3c), compound 1 was
only detected in the strains from group 7, which consisted of
Nocardia spp. along with two Micromonospora spp. After rapid
structure dereplication based on high resolution MS data of 1
(Figure 3), compound 1 was a new natural product that has
been targeted for structure determination but was beyond the
scope of this work.
Identifying compounds responsible for groups near the
center of the scores plot, such as group 4 (Strain WMMB-247,
Figure 3a), was not straightforward. However, observing
diﬀerent PC planes could separate these groups. As shown in
Figure 4a, WMMB-247 was separated in the PC1 vs PC4 plane.
Compounds unique to WMMB-247 were identiﬁed in the
corresponding loadings plot (Figure 4b). The major com-
pounds unique to WMMB-247 were elucidated as two rare
phenylacetyl-desferrioxamines (2−3) (Figure 4c). The struc-
tures of 2 and 3 were conﬁrmed using MS/MS and NMR
(Figures S3 and S4). The bucket statistics plot for compound 2
Figure 4. Discovery of natural products unique to strain WMMB-247. (a) PCA scores plot (PC1 vs PC4). The PC planes were adjusted to separate
WMMB-247. (b) PCA loadings plot. The loadings plot shows compounds (2−3) that were unique to WMMB-247. (c) Structures of 2 and 3. (d)
The bucket statistic plot of 2 (RT 7.4 min m/z 679.4026, [M + H]+). As shown, compound 2 was only detected in WMMB-247.
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compound was only detected in strain WMMB-247 (Figure
4d). Desferrioxamines 2 and 3 were recently reported and
promoted the growth of previously uncultivable bacteria when
released from neighboring strains.
39
Having success with strains grown in liquid, we tested LC/
MS-PCA to discover novel natural products from marine-
derived Streptomyces spp. grown on solid media. Fifty-three
marine-derived Streptomyces spp. cultivated from tropical
ascidians, Trididemnum orbiculatum and Didemnum psamma-
thode, were analyzed using LC/MS-PCA (Figure 5). In the
scores plot, strain WMMB-272 was clearly distinct from the
other strains, which indicated unique natural products.
Molecular formulas were identiﬁed through interactive analysis
of the loadings plot, and searches in databases indicated that the
compounds responsible for the variance observed in PCA were
new natural products. Subsequently, we puriﬁed the com-
pounds, elucidated their structures, and determined that they
were novel natural products (see 1D and 2D NMR assignment
in Table S2, Figure S5−S8). Although 4 and 5 were published
by Fenical and co-workers
40 during the preparation of this
paper, we independently discovered them using PCA.
Compound 6 was a new natural product, and this is the ﬁrst
report of the structure. In addition, we identiﬁed 20 out of the
53 Streptomyces spp. isolates produced a number of unique and
putative new natural products. The isolation and structure
elucidation of these compounds will be reported in due course.
Compared to traditional approaches, this method represented a
remarkably high discovery rate from Streptomyces spp.
Assessment of Microbial Natural Product Production
by Secondary Metabolomics. Secondary metabolomics was
also evaluated as a method to assess natural product
production. We hypothesized that LC/MS-PCA would be a
valuable tool to investigate regulation of biosynthesis. There-
fore, we selected a system where regulation was well
understood, desferrioxamine (iron siderophores) production
and regulation. Bacteria have developed sophisticated mecha-
nisms to regulate iron metabolism, which have been extensively
investigated.
41 A marine-derived Micromonospora sp. (WMMB-
224) was selected because it produced a diverse group of
desferrioxamine. Since desferrioxamine biosynthesis was shown
to be highly responsive to iron concentrations, the eﬀects of
iron in three growth media (ASW-A, ASW-K, and DI-A) (see
recipe in Table S3 in Supporting Information) on desferriox-
amine production was investigated. Using LC/MS-PCA, a total
of 30 conditions (Table S4 in Supporting Information) were
simultaneously analyzed. The grouping pattern in the PCA
scores plot was primarily based on the concentrations of iron
added and not on the type of iron added or the three media
types (Figures S1a and S2a,b in Supporting Information). After
examining the loadings plot (Figure S1b), a major diﬀerence
between group 1 and group 3 was the absence and presence of
compound 7 (putative new natural product RT 10.5 min m/z
431.2767, [M + H]+), respectively. As predicted, the other
major diﬀerence between group 1 and group 3 was primarily
due to the presence and absence of desferrioxamines,
respectively. However, desferrioxamine B (8) and desferriox-
amine D1 (9) in group 1 were observed as Fe3+-chelated forms
in group 3 (Figure S1b). This proof of concept suggests that
LC/MS-PCA would be a valuable tool for analyzing regulation
of biosynthesis.
In conclusion, LC/MS-PCA (“secondary metabolomics”)
was eﬀective for selecting strains to yield the most chemically
diverse and novel natural products for drug discovery.
Figure 5. Discovery of polyenepyrones from a marine-derived Streptomyces sp. (WMMB-272). (a) PCA scores plot indicated separation of strain
WMMB-272 from a collection of 53 marine-derived Streptomyces spp. (b) PCA loadings plot displayed compounds responsible for the separation.
Compounds (4−6) were isolated after scale-up fermentation. (c) Structures of compounds (4−6) were determined by NMR and MS. Compounds
4−6 belong to a rare class of polyenepyrones.
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with 16S phylogenetic trees, and those diﬀerences could easily
be observed using PCA. Overall, analysis of secondary
metabolites provided ﬁner resolution of strain diﬀerentiation
than 16S. Additionally, heat maps indicated that little chemical
redundancy was observed when selecting representative strains
for drug discovery. In the end, we have validated LC/MS-PCA
as a rapid method to select strains on the basis of laboratory
production of secondary metabolites. In addition to strain
selection, secondary metabolomics greatly assisted with
discovery of novel natural products and will be a useful tool
to study regulation of natural product biosynthesis. Overall,
these methods could enable a wide range of studies in the ﬁeld
of microbial natural products by drastically decreasing analysis
time compared to manual comparison of LC/MS chromato-
grams.
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